Drug Induced Psoriasis

Total Page:16

File Type:pdf, Size:1020Kb

Load more

Acta Dermatovenerol Croat 2011;19(1):39-42 REVIEW Drug Induced Psoriasis Višnja Milavec-Puretić, Marko Mance, Romana Čeović, Jasna Lipozenčić Department of Dermatology and Venereology, University Hospital Center Zagreb, School of Medicine University of Zagreb, Zagreb, Croatia Corresponding author: SUMMARY Psoriasis is a chronic inflammatory skin disorder clinically Prof. Višnja Milavec-Puretić, MD, PhD characterized by erythematous, sharply demarcated papules and rounded plaques covered by silvery micaceous scale. While the exact Department of Dermatology and Venereology causes of psoriasis have yet to be discovered, the immune system University Hospital Center Zagreb and genetics are known to play major roles in its development. Many School of Medicine University of Zagreb external factors including infections, stress and medications may ex- acerbate psoriasis. Some of the most common medications know to Šalata 4 trigger or worsen existing psoriasis include lithium, gold salts, beta HR-10000 Zagreb blockers and antimalarials. Exacerbation of psoriasis due to the fol- Croatia lowing medications has also been observed: adrenergic antagonists, [email protected] interferon, gemfibrozil, iodine, digoxin and chlonidine. Having re- viewed a variety of cases, we observed a relationship between cer- tain medications and documented their involvement in exacerbating Received: March 31, 2010 or inducing psoriasis. Accepted: December 29, 2010. KEY WORDS: psoriasis, drug eruption, drug induced psoriasis INTRODUCTION Psoriasis is a chronic inflammatory skin disorder triggers an immune response, which leads to T cell clinically characterized by erythematous, sharply de- activation and release of various cytokines. Co-stimu- marcated papules and rounded plaques covered by latory signals are initiated via interaction of adhesion silvery micaceous scale (1). While the exact causes of molecules on the antigen-presenting cells, such as psoriasis have yet to be discovered, the immune sys- lymphocyte function-associated antigen (LFA)-3 and tem and genetics are known to play major roles in its intercellular adhesion molecule-1, with their respec- development. The immune system is somehow mis- tive receptors CD2 and LFA-1 on T cells. Afterwards, takenly triggered, which speeds up the growth cycle these T cells are released into the circulation and re- of skin cells among other immune reactions (2). Cur- turn to the skin. T cell reactivation in the dermis and rent research suggests that the inflammatory mecha- epidermis and the local effect of cytokines such as nisms are immune based and most likely initiated tumor necrosis factor lead to the inflammation, cell- and maintained primarily by T cells in the dermis (3). mediated immune responses, and epidermal hyperp- Antigen-presenting cells in the skin, such as Langer- roliferation observed in patients with psoriasis. Also, hans cells, are believed to migrate from the skin to re- the interleukin (IL)-12-related cytokine, IL-23, was rec- gional lymph nodes, where they interact with T cells. ognized to be involved in the establishment of chron- Presentation of an as yet unidentified antigen to the ic inflammation and in the development of a T helper T cells, as well as a number of co-stimulatory signals, (Th)-cell subset producing IL-17 (Th17). These cells are ACTA DERMATOVENEROLOGICA CROATICA 39 Milavec-Puretić et al. Acta Dermatovenerol Croat Drug induced psoriasis 2011;19(1):39-42 very distinct from Th1 and Th2 populations and Th17 Table 1. Drugs responsible for the eruption of psoriasis cells are now recognized as a third T-effector cell sub- (11) set. The IL-23/IL-17 pathway has recently been impli- Acebutolol Ketoprofen cated in the induction and progression of a number Acitr patients etin Labetalol of inflammatory diseases, including psoriasis. Genetic Aldesleukin (interleukin 2) Letrozole Alefacept Levamizol factors also seem to have a role in the development Amiodarone Levobetaxolol and course of psoriasis: HLA-B13, -B17, DR7 and -Cw6 Amoxicillin Lithium are all associated with plaque psoriasis. Many fami- Ampicillin Metipranolol lies appear to exhibit autosomal dominant patterns Arpiprazole Modafinil of inheritance with decreased penetrance. Studies of Arsenic Morphine Aspirin Meclofenamate twin siblings have shown concordant disease in 73% Atenolol Mefloquine of monozygotic twins compared with 20% in dizy- Auranofin Mesalamine gotic twins. Several genetic susceptibility loci have Aurotioglucosis Methyltestosterone also been identified, including psoriasis susceptibility Betaxolol Metoprolol Bisoprolol Nadolol 1 (PSOR1) on chromosome 6, which is associated with Botulinum toxin (A & B) Omeprazole up to 50% of cases. Eight other psoriasis susceptibil- Captopril Oral contraceptives ity loci (PSOR2, PSOR3, PSOR4, PSOR5, PSOR6, PSOR7, Carbamazepine Peg interferon PSOR8 and PSOR9) have been discovered, as well as Carteolol Infliximab Carvedilol Penbutolol the transcription factor RUNX1 (4). Celecoxib Penicillamine Extrinsic factors are also important in the patho- Chlorambucil Pentostatin genesis of psoriasis, perhaps as triggers in genetically Chloroquine Perindopril susceptible patients. The role of streptococcal infec- Chlorthalidone Pindolol Cimetidine Potassium iodide tions has been suspected as a triggering factor for Citalopram Primaquine psoriasis for many decades, especially in children and Claritromycin Propranolol guttate forms. The role of streptococcal organisms in Clomipramine Psoralens chronic plaque psoriasis is less certain compared to Clonidine Paroxetine Co-trimoxazole Peginterferon the guttate form (5). Viral infections may also play a Cyclosporin Quinidine role in the etiology of psoriasis, as the eruption ap- Dexfenfluoramine Quinine pears, or the pre-existing disease is aggravated, by Diclofenac Rabeprazol an influenza-type illness. External trauma can induce Digoxin Ranitidine Diltiazem Risperidone local lesions of psoriasis (the Koebner or isomorphic Dipyridamole Ritonavir phenomenon) (6). Patients frequently complain that Diphenylhydatonin Rivastigmine psychological stress causes flares of psoriasis activ- Doxycycline Rofecoxib ity. Review of the literature suggests that stress from Doxorubicin Ropinirol major life events, and some personality traits such Efalizumab Saquinavir Eletriptan Sotalol as difficulty in expressing emotion, may play a role Enalapril Sodium chromoglycate in psoriasis (7). It is not known how stress induces or Esmolol Sulfamethoxazole aggravates psoriasis. Stress has effects on hormones, Etanercept Sulfasalazine and on the autonomic nervous and immune systems. Flecainide Sulfazolamine Fluorouracil Tacrine There is some evidence that psoriasis is associated Fluoxetine Terbinafine with a number of diseases strongly linked to alcohol Fluoxymesterone Terfenadine consumption and smoking (8,9). Foscarnet Testosterone Gancyclovir Tetracycline Many drugs have also been suspected to trig- Gemfibrozil Thalidomide ger psoriasis (10). There have been many medica- Glimepride Thiabendazole tions documented to directly cause the eruption of Glatiramer Thioguanine psoriasis (Table 1), along with others that have been Glipizide Tiagabine documented to induce psoriasis (Table 2). How these Glyburide Timolol Gold Trazodone different drugs with different chemical structures can Granulocyte colony-stimulating Ursodiol have the same effect is difficult to explain; they may factor (GCSF) Valdecoxib affect the psoriatic process at different stages but Henna Valproic acid with the same results. Hydroxyurea Venlafaxine Ibuprofen Voriconazole It is evident by the large number of associated Interferon alfa-2 Zaleplon medications linked to psoriasis seen in Tables 1 and 2 Interferon beta-1b that a great deal of thought and care must be invest- JZ Litt: Psoriasis. Drug eruption reference manual 2006:643. 40 ACTA DERMATOVENEROLOGICA CROATICA Milavec-Puretić et al. Acta Dermatovenerol Croat Drug induced psoriasis 2011;19(1):39-42 Table 2. Drugs responsible for the induction of psoriasis cases (20). In patients taking antipsychotic medica- (11) tions, Brauchli et al. found that between the identi- Acetazolamide Diclofenac fied 36,702 incident cases of psoriasis and the same Aminoglutethimide Diltiazem number of matched controls the use of 5 or more prescriptions for lithium and atypical antipsychot- Amiodarone Hydroxychloroquine ics yielded adjusted odds ratios (OR) of 1.68 (95% CI, Amoxicillin Indomethacin 1.18-2.39; P<0.01) and 0.76 (95% CI, 0.55-1.06; P=0.11), Ampicillin Lithium respectively. They also found that the OR for olanzap- Aspirin Methicillin ine was 0.50 (95% CI, 0.28-0.89, P=0.02), suggesting Atenolol Penicillins that long-term use of lithium was associated with a Chloroquine Potassium iodide small increase in the risk of incident psoriasis, while Cimetidine Propranolol there is a suggestion of a possible reduced psoriasis risk associated with the use of atypical antipsychot- Corticosteroids Terbinafine ics, mainly olanzapine (21). Bisoprolol, a commonly Cyclosporin used beta blocker, was found by Waqar and Sarkar to Litt JZ: Psoriasis. Drug eruption reference manual 2006:645. cause acute worsening of psoriasis within 72 hours of being prescribed in one of their patients (22). Thakor et al. documented the first reported case of ramipril- ed by the physician when choosing the appropriate induced psoriasis, which reminds us of the impor- therapy for patients. There is always a potential risk tance of recognizing new medications as the possible when prescribing
Recommended publications
  • ORIGINAL ARTICLE a Clinical and Histopathological Study of Lichenoid Eruption of Skin in Two Tertiary Care Hospitals of Dhaka

    ORIGINAL ARTICLE a Clinical and Histopathological Study of Lichenoid Eruption of Skin in Two Tertiary Care Hospitals of Dhaka

    ORIGINAL ARTICLE A Clinical and Histopathological study of Lichenoid Eruption of Skin in Two Tertiary Care Hospitals of Dhaka. Khaled A1, Banu SG 2, Kamal M 3, Manzoor J 4, Nasir TA 5 Introduction studies from other countries. Skin diseases manifested by lichenoid eruption, With this background, this present study was is common in our country. Patients usually undertaken to know the clinical and attend the skin disease clinic in advanced stage histopathological pattern of lichenoid eruption, of disease because of improper treatment due to age and sex distribution of the diseases and to difficulties in differentiation of myriads of well assess the clinical diagnostic accuracy by established diseases which present as lichenoid histopathology. eruption. When we call a clinical eruption lichenoid, we Materials and Method usually mean it resembles lichen planus1, the A total of 134 cases were included in this study prototype of this group of disease. The term and these cases were collected from lichenoid used clinically to describe a flat Bangabandhu Sheikh Mujib Medical University topped, shiny papular eruption resembling 2 (Jan 2003 to Feb 2005) and Apollo Hospitals lichen planus. Histopathologically these Dhaka (Oct 2006 to May 2008), both of these are diseases show lichenoid tissue reaction. The large tertiary care hospitals in Dhaka. Biopsy lichenoid tissue reaction is characterized by specimen from patients of all age group having epidermal basal cell damage that is intimately lichenoid eruption was included in this study. associated with massive infiltration of T cells in 3 Detailed clinical history including age, sex, upper dermis. distribution of lesions, presence of itching, The spectrum of clinical diseases related to exacerbating factors, drug history, family history lichenoid tissue reaction is wider and usually and any systemic manifestation were noted.
  • Drug Eruptions- When to Worry

    Drug Eruptions- When to Worry

    3/17/2017 Drug reactions: Drug Eruptions‐ When to Worry 3 things you need to know 1. Type of drug reaction 2. Statistics: – Which drugs are most likely to cause that type of Lindy P. Fox, MD reaction? Associate Professor 3. Timing: Director, Hospital Consultation Service – How long after the drug started did the reaction Department of Dermatology University of California, San Francisco begin? [email protected] I have no conflicts of interest to disclose 1 Drug Eruptions: Common Causes of Cutaneous Drug Degrees of Severity Eruptions • Antibiotics Simple Complex • NSAIDs Morbilliform drug eruption Drug hypersensitivity reaction Stevens-Johnson syndrome •Sulfa (SJS) Toxic epidermal necrolysis (TEN) • Allopurinol Minimal systemic symptoms Systemic involvement • Anticonvulsants Potentially life threatening 1 3/17/2017 Morbilliform (Simple) Drug Eruption Morbilliform (Simple) Drug Eruption Per the drug chart, the most likely culprit is: Per the drug chart, the most likely culprit is: Day Day Day ‐> ‐8 ‐7 ‐6 ‐5 ‐4 ‐3 ‐2 ‐1 0 1 Day ‐> ‐8 ‐7 ‐6 ‐5 ‐4 ‐3 ‐2 ‐1 0 1 A vancomycin x x x x A vancomycin x x x x B metronidazole x x B metronidazole x x C ceftriaxone x x x C ceftriaxone x x x D norepinephrine x x x D norepinephrine x x x E omeprazole x x x x E omeprazole x x x x F SQ heparin x x x x F SQ heparin x x x x trimethoprim/ trimethoprim/ G xxxxxxx G xxxxxxx sulfamethoxazole sulfamethoxazole Admit day Rash onset Admit day Rash onset Morbilliform (Simple) Drug Eruption Drug Induced Hypersensitivity Syndrome • Begins 5‐10 days after drug started
  • Psoriasiform Drug Eruption Induced by Anti-Tuberculosis Medication: Potential Role of Plasma­ Cytoid Dendritic Cells

    Psoriasiform Drug Eruption Induced by Anti-Tuberculosis Medication: Potential Role of Plasma­ Cytoid Dendritic Cells

    Letters to the Editor 305 Psoriasiform Drug Eruption Induced by Anti-tuberculosis Medication: Potential Role of Plasma- cytoid Dendritic Cells Jae-Jeong Park1, Yoo Duk Choi2, Jee-Bum Lee1, Seong-Jin Kim1, Seung-Chul Lee1, Young Ho Won1 and Sook Jung Yun1* Departments of 1Dermatology and 2Pathology, Chonnam National University Medical School, 8 Hak-Dong, Dong-Gu, Gwangju, 501-757, Korea. *E mail: [email protected] Accepted November 23, 2009. Psoriasiform drug eruptions can be induced by several one month earlier, and treated with bicalutamide and tamsulosin drugs (1). Psoriasis is a chronic inflammatory disease hydrochloride, which were started one week after the skin eruption began. The skin lesions spread from his arms to the trunk and lower characterized by T-cell-mediated cytokine production extremities. On physical examination, erythematous papulosqua- that drives the hyperproliferation and abnormal differen- mous lesions were found, scattered on his trunk, arms, hands, legs, tiation of keratinocytes (2). Drugs can cause new lesions and buttocks (Fig. 1). Other than an elevated eosinophil count (731/ when there is no history or family history of psoriasis. mm3, normal range 0–483/mm3; 10.6%, normal range 0–7%) and Based on the psoriatic drug eruption probability score, IgE level (361 IU/ml, normal range 0–100 IU/ml), the laboratory findings were within normal limits, including a complete blood β‑blockers, synthetic anti‑malaria drugs, non‑steroidal cell count, liver and renal function tests, and urinalysis. Syphilis anti‑inflammatory drugs (NSAIDs), lithium, digoxin, and Venereal Disease Research Laboratory (VDRL) and Treponema tetracycline antibiotics are relevant in psoriasis (1, 3–5).
  • Drug Eruptions

    Drug Eruptions

    DRUG ERUPTIONS http://www.aocd.org A drug eruption is an adverse skin reaction to a drug. Many medications can cause reactions, especially antimicrobial agents, sulfa drugs, NSAIDs, chemotherapy agents, anticonvulsants, and psychotropic drugs. Drug eruptions can imitate a variety of other skin conditions and therefore should be considered in any patient taking medications or that has changed medications. The onset of drug eruptions is usually within 2 weeks of beginning a new drug or within days if it is due to re-exposure to a certain drug. Itching is the most common symptom. Drug eruptions occur in approximately 2-5% of hospitalized patients and in greater than 1% of the outpatient population. Adverse reactions to drugs are more prevalent in women, in the elderly, and in immunocompromised patients. Drug eruptions may be immunologically or non-immunologically mediated. There are 4 types of immunologically mediated reactions, with Type IV being the most common. Type I is immunoglobulin-E dependent and can result in anaphylaxis, angioedema, and urticaria. Type II is cytotoxic and can result in purpura. Type III reactions are immune complex reactions which can result in vasculitis and type IV is a delayed-type reaction which results in contact dermatitis and photoallergic reactions. This is important as different medications are associated with different types of reactions. For example, insulin is related with type I reactions whereas penicillin, cephalosporins, and sulfonamides cause type II reactions. Quinines and salicylates can cause type III reactions and topical medications such as neomycin can cause type IV reactions. The most common drugs that may potentially cause drug eruptions include amoxicillin, trimethoprim sulfamethoxazole, ampicillin, penicillin, cephalosporins, quinidine and gentamicin sulfate.
  • My Approach to Superficial Inflammatory Dermatoses K O Alsaad, D Ghazarian

    My Approach to Superficial Inflammatory Dermatoses K O Alsaad, D Ghazarian

    1233 J Clin Pathol: first published as 10.1136/jcp.2005.027151 on 25 November 2005. Downloaded from REVIEW My approach to superficial inflammatory dermatoses K O Alsaad, D Ghazarian ............................................................................................................................... J Clin Pathol 2005;58:1233–1241. doi: 10.1136/jcp.2005.027151 Superficial inflammatory dermatoses are very common and diagnosis of inflammatory skin diseases, there are limitations to this approach. The size of the comprise a wide, complex variety of clinical conditions. skin biopsy should be adequate and representa- Accurate histological diagnosis, although it can sometimes tive of all four compartments and should also be difficult to establish, is essential for clinical include hair follicles. A 2 mm punch biopsy is too small to represent all compartments, and often management. Knowledge of the microanatomy of the skin insufficient to demonstrate a recognisable pat- is important to recognise the variable histological patterns tern. A 4 mm punch biopsy is preferred, and of inflammatory skin diseases. This article reviews the non- usually adequate for the histological evaluation of most inflammatory dermatoses. However, a vesiculobullous/pustular inflammatory superficial larger biopsy (6 mm punch biopsy), or even an dermatoses based on the compartmental microanatomy of incisional biopsy, might be necessary in panni- the skin. culitis or cutaneous lymphoproliferative disor- ders. A superficial or shave biopsy should be ..........................................................................
  • Drug Eruption

    Drug Eruption

    Drug eruption March 25,2015 Outline • Clinical features • Pathogenesis • How to approach? • Management? Need to know • Urticaria • Exanthematous rash • DRESS • Stevens-Johnson syndrome/TEN • Fix drug eruptions • Acute generalized exanthematous pustulosis • Photoallergic/Phototoxic. • Chemotherapy induced.. Generalized erythematous and slightly edematous maculopapular rashes Erythema and edema of face and periorbital area Investigations 28/8/47 30/8/47 2/9//47 Total 1110 1690 2024 Eosinophil SGOT 42 98 69 SGPT 130 108 88 Your Dx is D R E S S ? Drug Rash with Eosinophilia and Systemic Symptoms DRESS • Aromatic antiepileptic agents (phenytoin, carbamazepine, phenobarbital) • Sulfonamides, allopurinol, gold salts, dapsone, and minocycline. 5 days after prednisolone 30mg/d 5 days after prednisolone 30mg/d Gout after 2 weeks of allopurinol Toxic Epidermal Necrolysis from allopurinol Approach to the Acute Generalized Blistering Patient History : Onset ,underlying disease, New Drug ,other symptoms? ( fever,sore throat ) Physical examination : target lesion nikolsky sign, epidermal necrolysis, mucosal involvement Investigation : baseline lab,skin biopsy + Direct Immonofluorescence Differential diagnosis of TEN • SSSS (Staphylococcal scalded skin syndrome ) • Autoimmune blistering disease ( pemphigus,linear IgA dermatosis.. ) • Erythema multiforme Generalized exanthem Blistering ,denudation Generalized Cutaneous tenderness Nikolsky sign + desquamation Apoptosis desmoglein-1 TEN SSSS Pemphigus vulgaris Bullous pemphigoid Erythema multiforme Take
  • UC Davis Dermatology Online Journal

    UC Davis Dermatology Online Journal

    UC Davis Dermatology Online Journal Title Morbilliform eruption related to eltrombopag: emerging data on the cutaneous toxicity of thrombopoietin receptor agonists Permalink https://escholarship.org/uc/item/8pk3534w Journal Dermatology Online Journal, 22(6) Authors Kazemi, Tiana Martin, Sabrina Worswick, Scott Publication Date 2016 DOI 10.5070/D3226031325 License https://creativecommons.org/licenses/by-nc-nd/4.0/ 4.0 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Volume 22 Number 6 June 2016 Case presentation Morbilliform eruption related to eltrombopag: emerging data on the cutaneous toxicity of thrombopoietin receptor agonists Tiana Kazemi BA1, Sabrina Martin MD2, Scott Worswick MD2 Dermatology Online Journal 22 (6): 13 1 David Geffen School of Medicine at UCLA 2 Department of Medicine, David Geffen School of Medicine at UCLA Correspondence: Scott Worswick 200 Medical Plaza Suite 450 Los Angeles CA, 90095 Tel. (310) 917-3376 [email protected] Abstract Eltrombopag is a thrombopoietin mimetic used for the treatment of thrombocytopenia in patients with chronic immune thrombocytopenia, hepatitis C patients undergoing antiviral therapy, and thrombocytopenia secondary to aplastic anemia that is refractory to immunosuppressive therapy. We report a case of a 25-year-old man with a history of aplastic anemia who presented with fever and a monomorphic papular rash. Subsequent labs, biopsy, and clinical course favored drug-induced cutaneous toxicity, with eltrombopag as the likely culprit. Eltrombopag is generally well-tolerated; however, clinicians should be aware of the possibility of dose-independent drug-induced cutaneous toxicity with this medication. This report reviews the mechanism and use of eltrombopag along with a summary of associated adverse cutaneous reactions.
  • Meeting Program

    Meeting Program

    November 6–9, 2014 Chicago Hilton & Towers | Chicago, IL USA Meeting Program www.asdp.org/AM14 #ASDP2014 Chicago Hilton and Towers Mini Course First Floor Young Physicians’ Reception Second Floor Registration/ASDP Art Show/Posters/ Dermatopathology Bookstore/ ASDP Career Center Short Courses/Young Physicians’ Forum/ Duel in Dermatopathology/Basic Science Course/ Helwig Lecture/Fellows’ Case Presentations/ Evening Slide Symposium/Oral Abstract Sessions Self-Assessment Discussion/ Membership Business Meeting and Luncheon Evening Slide Symposium Preview Consultations in Dermatopathology Third Floor Speaker Ready Room Self-Assessment in Dermatopathology/ ASDP Quality and Performance Improvement Program/Slide Library Meeting Program Table of Contents General Information General General .......................................................................4 – 14 Information Information Faculty Disclosures .......................................................................10 – 11 2014 Founders’ and Nickel Award Recipients ...............................12 – 13 Corporate Partners and Sponsors......................................................... 14 Program-at-a-Glance ...................................................................15 – 22 Glance Plenary Program ..........................................................................23 – 51 Program-at-a- Thursday, November 6 .............................................................23 – 31 Friday, November 7 ..................................................................32 –
  • Psoriasiform Drug Eruption Secondary to Sorafenib: Case Series and Review of the Literature

    Psoriasiform Drug Eruption Secondary to Sorafenib: Case Series and Review of the Literature

    CASE REPORT Psoriasiform Drug Eruption Secondary to Sorafenib: Case Series and Review of the Literature Courtney J. Ensslin, MD; Pei-han Kao, MD; Ming-ying Wu, MD; Yao-yu Chang, MD; Tseng-tong Kuo, MD, PhD; Chia-hsun Hsieh, MD, MS; Sen-yung Hsieh, MD, PhD; Chih-hsun Yang, MD; Lloyd S. Miller, MD, PhD he expanded use of targeted anticancer agents PRACTICE POINTS such as sorafenibcopy has revealed a growing spec- • The use of targeted anticancer agents continues T trum of adverse cutaneous eruptions. We describe to expand. With this expansion, the number and 3 patients with sorafenib-induced psoriasiform dermatitis type of cutaneous adverse events continues and review the literature of only 10 other similar reported to increase. cases based on a search of PubMed, Web of Science, and • Although sorafenib is known to cause various Americannot Society of Clinical Oncology abstracts using the dermatologic side effects, there are few reports of terms psoriasis or psoriasiform dermatitis and sorafenib.1-10 psoriasiform dermatitis. We seek to increase awareness of this particular drug • Increased awareness of sorafenib-induced pso- Doeruption in response to sorafenib and to describe poten- riasiform dermatitis and its management is vital to tial effective treatment options, especially when sorafenib prevent discontinuation of potentially life-saving anti- cannot be discontinued. cancer therapy. Case Reports Patient 1—A 68-year-old man with chronic hepatitis B infection and hepatocellular carcinoma (HCC) was started The expanding use of novel targeted anticancer agents such as sorafenib has led to an increasing number of dermatologic on sorafenib 400 mg daily.
  • Drug-Induced Subacute Cutaneous Lupus Erythematosus: a Paradigm for Bedside-To-Bench Patient-Oriented Translational Clinical Investigation

    Drug-Induced Subacute Cutaneous Lupus Erythematosus: a Paradigm for Bedside-To-Bench Patient-Oriented Translational Clinical Investigation

    Arch Dermatol Res (2009) 301:65–70 DOI 10.1007/s00403-008-0890-x REVIEW Drug-induced subacute cutaneous lupus erythematosus: a paradigm for bedside-to-bench patient-oriented translational clinical investigation Richard D. Sontheimer Æ Clifford L. Henderson Æ Renee H. Grau Received: 15 August 2008 / Accepted: 22 August 2008 / Published online: 17 September 2008 Ó Springer-Verlag 2008 Abstract At least 71 patients have been reported in which blockers, angiotensin converting enzyme (ACE) inhibitors, their otherwise typical subacute cutaneous lupus erythe- beta-blockers). An approach to the management of DI- matosus (SCLE) skin lesions were felt to have been SCLE is presented. Ro/SS-A autoantibodies tended to temporally associated with the systemic administration of a remain present in the blood after resolution of drug-induced drug. The mean age of this cohort of drug-induced SCLE SCLE skin lesions. A common link between the disparate (DI-SCLE) patients was 59 years of age which is somewhat group of drug structures implicated in triggering SCLE is older than the mean age of previously reported idiopathic their tendencies to produce photosensitivity and lichenoid SCLE patient cohorts. Patients had been taking the sus- drug reactions. This leads to the speculation that DI-SCLE pected triggering drug for weeks to years before the onset of could represent a photo-induced isomorphic/Ko¨ebner SCLE skin lesions. In addition, it was not unusual for 2– response in an immunogenetically predisposed host. 3 months to be required for resolution of the SCLE skin lesions following discontinuation of the triggering drug. A Keywords relatively large number of drugs representing different Drug-induced subacute cutaneous lupus erythematosus Á pharmacological classes have been implicated in the Bedside-to-bench patient-oriented translational clinical induction of SCLE.
  • Drug Eruptions by the Numbers

    Drug Eruptions by the Numbers

    AMERICAN ACADEMY OF DERMATOLOGY SKIN DISEASE BRIEFS Drug eruptions by the numbers Drug eruptions are among 24 skin diseases or disease categories examined in the Burden of Skin Disease report commissioned by the American Academy of Dermatology. The report examined prevalence, economic burdens, and mortality for skin disease in the U.S. using 2013 health care claims data drawn from insurance enrollment and claims databases and found that: • 84.5 million Americans — one in four — were impacted by skin disease; 50% of them are over 65 and have an average of 2.2 skin conditions. • Skin disease cost the U.S. healthcare system $75 billion in medical, preventative, and prescription and non-prescription drug costs. • One in three Americans with skin disease were seen by a dermatologist, who collaborate with other physicians throughout the health care system in caring for these patients. Drug eruptions on the skin primarily affected children and young adults, with those age 44 or younger accounting for approximately 62% of the more than 773,000 Americans who sought medical treatment in 2013. Drug eruptions: • Cost patients an average of nearly $343 in 2013, surpassing the cost per patient for vitiligo, pruritus and urticaria combined, and non-cancerous skin growths. • Cost the health care system a total of $266 million and resulted in lost productivity costs of $44 million in 2013. • Caused more than 100 deaths in 2013, with patients lives potentially shortened by 11 years due to the disease. The charts that follow provide topline data on how drug eruptions contribute to the overall burden of skin disease.
  • A Rare Side Effect Seen Due to the Use of Apixaban: Palmoplantar Psoriasiform Drug Eruption

    A Rare Side Effect Seen Due to the Use of Apixaban: Palmoplantar Psoriasiform Drug Eruption

    Anatol J Cardiol 2016; 16: 212-5 Case Reports 213 with “normal” P waves on ECG. P-wave morphology is usually 4. Fox K, Ford I, Steg PG, Tendera M, Ferrari R. Ivabradine for patients similar or identical to sinus rhythm. In general, IST is a diagno- with stable coronary artery disease and left-ventricular systolic sis made by exclusion. The treatment for IST has been limited dysfunction (BEAUTIFUL): a randomized, double- blind, placebo- to calcium channel blockers, beta-blockers, antiarrhythmic controlled trial. Lancet 2008; 372 :807-16. 5. Mason PK, Di Marco JP. New pharmacological agents for arrhyth- drugs, and sometimes, radiofrequency ablation. Although mias. Circ Arrhythm Electrophysiol 2009; 2: 588-97. metoprolol, verapamil, and digoxin were used in maximum 6. Rakovec P. Treatment of inappropriate sinus tachycardia with iva- doses in our patient, the control of HR was not achieved and bradine. Wien Klin Wochensch 2009; 121: 716-8. LVEF deteriorated each day, which led to the development of 7. Babic Z, Gabric ID, Pintaric H. Successful primary percutaneous symptomatic HF. coronary intervention in the first trimester of pregnancy. Catheter The most popular choice for patients with drug-refractory Cardiovasc Interv 2011; 77: 522–5. IST is sinus node modification using radiofrequency ablation (2, 8. Winum PF, Cayla G, Rubini M, Beck L, Messner-Pellenc P. A case of cardiomyopathy induced by inappropriate sinus tachycardia 3). However, our patient did not agree to undergo the procedure and cured by ivabradine. Pacing Clin Electrophysiol 2009; 32: because of risks such as ionizing radiation, phrenic nerve injury, 942-4. requirement for permanent pacing, and pericarditis.